Certified Advisory Corp Nektar Therapeutics Transaction History

Certified Advisory Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $12,142 - $14,993	-735 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$16.56 - $25.46 $8,280 - $12,730	-500 Reduced 40.49%	735 $15,000
Q1 2020 Apr 27, 2020	BUY	$14.47 - $27.96 $7,669 - $14,818	530 Added 75.18%	1,235 $22,000
Q3 2019 Nov 12, 2019	SELL	$16.91 - $36.27 $19,108 - $40,985	-1,130 Reduced 61.58%	705 $13,000
Q2 2019 Aug 07, 2019	SELL	$31.0 - $36.3 $1,364 - $1,597	-44 Reduced 2.34%	1,835 $65,000
Q1 2019 May 07, 2019	SELL	$31.58 - $46.35 $36,632 - $53,766	-1,160 Reduced 38.17%	1,879 $63,000
Q4 2018 Feb 04, 2019	SELL	$30.43 - $56.65 $1,704 - $3,172	-56 Reduced 1.81%	3,039 $100,000
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $4,646 - $6,848	100 Added 3.34%	3,095 $189,000
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $5,133 - $11,593	111 Added 3.85%	2,995 $146,000
Q1 2018 Apr 30, 2018	BUY	$57.4 - $108.44 $22,845 - $43,159	398 Added 16.01%	2,884 $306,000
Q4 2017 Feb 22, 2018	BUY	$23.02 - $60.5 $57,227 - $150,403	2,486	2,486 $148,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $249M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Certified Advisory Corp, based on Form 13F filings with the SEC.

Stay updated on Certified Advisory Corp with notifications on news.